Drug Profile
Research programme: vasopressin receptor antagonists - AbbVie
Alternative Names: ABT-558Latest Information Update: 23 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class
- Mechanism of Action Vasopressin 1b receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder